Hundreds of children living with spinal muscular atrophy (SMA) are set to benefit from two life-changing treatments, which have now received official approval for routine use across the NHS.
Nusinersen, an injectable drug and the first disease-modifying therapy for SMA, alongside the oral treatment risdiplam, were previously only available through a special access scheme.
